- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02067104
Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
A Placebo Controlled Double-Blind Study to Evaluate the Efficacy of Vismodegib as Chemoprevention of New Bcc Development in High Risk Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this study will be to determine if vismodegib pulse therapy will significantly reduce the incidence of newly diagnosed basal cell carcinomas (BCC) in high risk individuals when compared with placebo, as measured by the incidence of biopsy confirmed BCC over a 24 month period.
The secondary objective will be to determine that there will be no difference in the incidence of newly diagnosed squamous cell carcinomas (SCC) in the same subjects receiving vismodegib treatment when compared with placebo, as measured by the incidence of biopsy confirmed SCC over the same 24 month period.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- University of Arizona Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all pertinent aspects
- Comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- At least 18 years of age at the time of informed consent.
- History of 3 or more biopsy confirmed BCCs in the preceding 2 years, calculated from 2 years prior to the screening visit.
- No active skin cancers.
- Women of reproductive potential must agree to use two forms of acceptable contraception
- Male subjects must agree to use condoms at all times, even after a vasectomy, during sexual intercourse with female partners of reproductive potential during treatment with vismodegib and for 2 months after the last dose to avoid exposing a pregnant partner and the unborn fetus to vismodegib.
- Male patients must agree not to donate sperm during the study and for 2 months after discontinuation of vismodegib
- Agreement not to donate blood or blood products during the study and for 7 months after the last dose.
- Ability to understand and the willingness to sign a written informed consent document in English
Exclusion Criteria:
- Women who are pregnant or lactating, or planning pregnancy while enrolled in the study or for 7 months after the last dose of the study drug.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Subjects with clinically stable chronic medical conditions including, but not limited to, controlled hypertension, diabetes mellitus type II, hypercholesterolemia, or osteoarthritis, will be allowed to enter the study.
- Inability or unwillingness to swallow capsules.
- Have a history of alcohol of substance abuse, unless in full remission for greater than 6 months prior to the screening visit (Day 0) when the consent form is signed.
- Known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C viruses.
- Currently receiving vismodegib, biologics or chemotherapy
- Currently undergoing treatment with photodynamic therapy, topical chemotherapy agents including Imiquimod, fluorouracil
- Subjects who have Gorlins syndrome
- Subjects who have received any type of solid organ transplant
- Subjects taking immunosuppressive medications at the screening visit. (Day 0)
- Participation in other study using an investigational or experimental therapy or procedure within 4 weeks or 5 half-lives (whichever is longer) before the screening visit and/or during study participation. Subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study.
- Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- Subjects unable or unwilling to comply with the study visit schedule and requirements of the study
- Subjects unable to speak and read the English language
- A subject who, in the opinion of the sponsor-investigator will be uncooperative or unable to comply with study procedures.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
receive 150 mg of oral placebo daily for a period of 2 months
|
Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
|
Experimental: Vismodegib
receive 150 mg of vismodegib daily for a period of 2 months
|
Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Effect of Vismodegib Pulse Therapy on the Incidence of Newly Diagnosed Basal Cell Carcinomas (BCC)
Time Frame: 24 Months
|
Measured by the incidence of biopsy confirmed BCC over a 24 month period
|
24 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Incidence of Newly Diagnosed Squamous Cell Carcinomas (SCC) in the Same Subjects Receiving Vismodegib Treatment When Compared With Placebo
Time Frame: 24 Months
|
Measured by the incidence of biopsy confirmed SCC over the same 24 month period
|
24 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Clara Curiel-Lewandroski, University of Arizona
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1401183410
- ML28585 (Other Identifier: Genentech BioOncology)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Basal Cell Carcinomas
-
Bispebjerg HospitalUnknownPhotodynamic Therapy | Basal Cell CarcinomasDenmark
-
Novartis PharmaceuticalsTerminatedSporadic Superficial and Nodular Skin Basal Cell CarcinomasAustria, Australia
-
University Hospital, BordeauxInstitut National de la Santé Et de la Recherche Médicale, FranceRecruitingBasal Cell Carcinomas | Cutaneous Squamous Cell CarcinomaFrance
-
PellePharm, Inc.Completed
-
UCSF Benioff Children's Hospital OaklandCompletedBasal Cell CarcinomasUnited States
-
Hoffmann-La RocheCompletedBasal Cell CarcinomaUnited States, Spain, France, Germany, Netherlands, Russian Federation, Italy, Mexico, Austria, Canada
-
QLT Inc.NovartisTerminatedNevoid Basal Cell Carcinoma Syndrome | Basal Cell Carcinoma | Gorlin Syndrome
-
University of ArizonaGenentech, Inc.CompletedBasal Cell CarcinomaUnited States
-
UCSF Benioff Children's Hospital OaklandGenentech, Inc.CompletedBasal Cell Nevus Syndrome | Gorlin's SyndromeUnited States
-
Novartis PharmaceuticalsCompletedTreatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome PatientsAustria, Switzerland
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States